As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...

Ivim takes a comprehensive approach to obesity care and its customized patient-centric plans are carefully overseen by ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Register today to learn how to build an effective, sustainable GLP-1 strategy that benefits everyone on your health plan.

Shares of Hims & Hers Health ( HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.